ClinicalTrials.gg
CompletedNCT07294235Updated Oct 15, 2026

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

A Phase 1 interventional study of BGM1812 and Placebo in Overweight or Obesity, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd. — none open to participants now, none under way, none of them phase 3. Obesity · BrightGene Bio-Medical Technology Co., Ltd..

Enrollment
7th of 11
60 · median 75
Started
2025
with 7 others
Phase 1
8 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd., this one is the 7th largest by enrollment, is one of 8 that started in 2025, is one of 8 in phase 1, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd. is open now. The open studies under Obesity, anywhere →

Where they have run

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd. as a file.
02

Study summary

The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 60 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18 and 65 years (inclusive) at the time of screening , healthy and non-diabetic overweight or obese subjects , both male and female;
  • Healthy subjects , male weight ≥ 50 kg, female weight ≥ 45 kg, and (BMI): 20.0 kg/m² ≤ BMI \< 24 kg/m²(BMI = weight/height²);
  • Obese individuals: BMI ≥ 28.0 kg/m², or overweight individuals: 24.0 kg/m² ≤ BMI \< 28.0 kg/m²;
  • (Medical Inquiry) Have a stable body weight (\<5% self-reported change during the previous 12 weeks) before screening.
  • Have no history of mental disorders, be able to communicate smoothly with Investigator, Capable of understanding the written document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.
  • Male subjects with female partners of must agree to practice abstinence or to use a condom (male subject) plus an additional medically acceptable form of (female partner) for the duration of the study and for at least 3 months after dosing; must also agree to refrain from sperm donation for at least 3 months post dose.

Exclusion criteria

Exclusion Criteria:

  • Those with a history of severe drug allergies (especially those with known or suspected allergies to related compounds of BGM1812), or complicated with severe specific allergic diseases/history, or with a severe allergic constitution.
  • Subjects with positive results for , anti-, anti- or anti-TP during the screening period.
  • 12-lead shows ventricular heart rate \< 50 beats/min or > 100 beats/min at screening/baseline, second or third degree atrioventricular block, long syndrome, QTcF> 470ms for women or > 450ms for men, pre-excitation syndrome or other significant arrhythmias.
  • Used illegal drugs within 6 months prior to screening, or substance abuse within 12 months prior to screening.
  • Participated in drug or medical device clinical trials and treated with Study Drug (excluding placebo) or medical device intervention within 12 weeks before screening.
  • Participants who have received any vaccine within 2 weeks prior to screening, or plan to receive a vaccine during the trial.
  • Female participants who are pregnant or lactating, or those with a positive pregnancy test result during the screening period.
  • Positive urine drug test or alcohol serum test result at screening or at baseline.
  • Has any other conditions or disorders deemed unsuitable for including in the study, in the opinion of the Investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    BGM1812(Part A)

    Single ascending doses of BGM1812 administered subcutaneously (SC)

    Drug: BGM1812

  • Placebo comparator
    Placebo (Part A)

    Placebo administered SC

    Drug: Placebo

  • Experimental
    BGM1812 (Part B)

    Multiple ascending doses of BGM1812 administered SC.

    Drug: BGM1812

  • Placebo comparator
    Placebo (Part B)

    Placebo administered SC.

    Drug: Placebo

Interventions

  • DrugBGM1812

    AdministeredSC

  • DrugPlacebo

    Administered SC

  • DrugBGM1812

    Administered SC

  • DrugPlacebo

    Administered SC

07

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator

    Number of participants with AEs and SAEs will be assessed with reference to CTCAE V5.0

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

Secondary outcomes

  1. Pharmacokinetic (PK): Maximum Concentration (Cmax) of BGM1812

    PK Cmax of BGM1812

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of BGM1812

    PK:AUC of BGM1812

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  3. Pharmacodynamics (PD): Fasting Blood Glucose of BGM1812

    PD: Changes in fasting blood glucosebefore and after administration, and differences in the amount of change among different dose groups

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  4. PD:C-Peptide of BGM1812

    PD: Changes in C-peptide before and after administration, and differences in the amount of change among different dose groups

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  5. PD: Insulin of BGM1812

    PD: Changes in insulin before and after administration, and differences in the amount of change among different dose groups

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  6. PD: Body Weight of BGM1812

    PD: Changes in body weight before and after administration, and differences in the amount of change among different dose groupsPD: Changes in body weight before and after administration, and differences in the amount of change among different dose groups

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  7. PD: Waist Circumference of BGM1812

    PD: Changes in waist circumference before and after administration, and differences in the amount of change among different dose groups

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

  8. Anti-drug antibodies (ADA) of the study drug and their titers

    Detect the anti-drug antibodies (ADA) of the study drug and their titers; if the ADA is positive, neutralizing antibodies (NAb) will be further detected.

    Time frame: Baseline to Study Completion (Up to 6-9weeks)

08

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Chinese Medicine
    Kunming, Yunnan 650000, China
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 6 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Mar 2026 → Jun 2026 and completion Mar 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 19, 2025
StartActual
Dec 5, 2025
Primary completionActual
Jun 5, 2026was Mar 2026
CompletionActual
Jun 5, 2026was Mar 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Primary completion
Mar 2, 2026→Jun 5, 2026 (actual)
Oct 15, 2026
Study completion
Mar 2, 2026→Jun 5, 2026 (actual)
Oct 15, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Immunogenicity EndpointsNow Anti-drug antibodies (ADA) of the study drug and their titersTime frame: Baseline to Study Completion (Up to 6-9weeks)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Completed
    Primary completion Mar 2, 2026→Jun 5, 2026 (now actual)
    Study completion Mar 2, 2026→Jun 5, 2026 (now actual)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Immunogenicity EndpointsNow Anti-drug antibodies (ADA) of the study drug and their titersTime frame: Baseline to Study Completion (Up to 6-9weeks)
    + 4 other changes: verification date, responsible party, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07294235
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Dec 5, 2025
Primary completion
Jun 5, 2026
Completion
Jun 5, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion